Psychemedics Corporation (PMD) 

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

Show less

Over the last 12 months, insiders at Psychemedics Corporation have bought $0 and sold $59,182 worth of Psychemedics Corporation stock.

On average, over the past 5 years, insiders at Psychemedics Corporation have bought $83,708 and sold $59,182 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100 shares for transaction amount of $495 was made by SCHAFFER MICHAEL I (VP of Laboratory Operations) on 2022‑12‑16.